Do analysts prefer WEED or MJN?

Canopy Growth currently has a consensus target price of C$1.88, suggesting a potential upside of 73.61%. Given Canopy Growth's stronger consensus rating and higher probable upside, research analysts clearly believe Canopy Growth is more favorable than Cronos Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, WEED or MJN?

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canopy Growth C$293.63M 1.56 -C$1.05B -C$0.67 N/A Cronos Group N/A N/A N/A N/A N/A

Which has better valuation and earnings, WEED or CRON?

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canopy Growth C$293.63M 1.56 -C$1.05B -C$0.67 N/A Cronos Group C$179.09M 9.34 -C$32.78M C$0.19 23.89

Do analysts prefer CARA or WEED?

Canopy Growth has a consensus price target of C$1.88, suggesting a potential upside of 73.61%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than Cara Operations. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Operations 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has preferable valuation and earnings, CARA or WEED?

Cara Operations has higher earnings, but lower revenue than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cara Operations N/A N/A N/A N/A N/A Canopy Growth C$293.63M 1.56 -C$1.05B -C$0.67 N/A

Does the media refer more to WEED or GUD?

In the previous week, Canopy Growth and Canopy Growth both had 1 articles in the media. Canopy Growth's average media sentiment score of 0.71 beat Knight Therapeutics' score of 0.32 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Knight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Canopy Growth (WEED) Competitors

C$1.05 -0.03 (-2.78%)

As of 11:04 AM Eastern

Compare

WEED vs. MJN, CRON, CARA, GUD, and DHT.UN

Should you buy Canopy Growth stock or one of its competitors? Canopy Growth's main competitors and comparable companies include Cronos Group (MJN), Cronos Group (CRON), Cara Operations (CARA), Knight Therapeutics (GUD), and DRI Healthcare Trust (DHT.UN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Canopy Growth compare to Cronos Group?

Canopy Growth (TSE:WEED) and Cronos Group (CVE:MJN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Cronos Group has a net margin of 0.00% compared to Canopy Growth's net margin of -73.95%. Cronos Group's return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-73.95%	-29.85%	-3.83%
Cronos Group	N/A	N/A	N/A

In the previous week, Canopy Growth had 1 more articles in the media than Cronos Group. MarketBeat recorded 1 mentions for Canopy Growth and 0 mentions for Cronos Group. Canopy Growth's average media sentiment score of 0.71 beat Cronos Group's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Overall Sentiment
Canopy Growth	Positive
Cronos Group	Neutral

Canopy Growth currently has a consensus target price of C$1.88, suggesting a potential upside of 73.61%. Given Canopy Growth's stronger consensus rating and higher probable upside, research analysts clearly believe Canopy Growth is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.3% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cronos Group has lower revenue, but higher earnings than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$293.63M	1.56	-C$1.05B	-C$0.67	N/A
Cronos Group	N/A	N/A	N/A	N/A	N/A

Summary

Canopy Growth beats Cronos Group on 8 of the 11 factors compared between the two stocks.

How does Canopy Growth compare to Cronos Group?

Canopy Growth (TSE:WEED) and Cronos Group (TSE:CRON) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

4.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 4.4% of Cronos Group shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Comparatively, 46.4% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$293.63M	1.56	-C$1.05B	-C$0.67	N/A
Cronos Group	C$179.09M	9.34	-C$32.78M	C$0.19	23.89

Canopy Growth has a beta of 2.406513, indicating that its share price is 141% more volatile than the broader market. Comparatively, Cronos Group has a beta of 1.288385, indicating that its share price is 29% more volatile than the broader market.

Canopy Growth presently has a consensus target price of C$1.88, suggesting a potential upside of 73.61%. Cronos Group has a consensus target price of C$4.92, suggesting a potential upside of 8.30%. Given Canopy Growth's higher possible upside, equities analysts plainly believe Canopy Growth is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cronos Group has a net margin of 38.95% compared to Canopy Growth's net margin of -73.95%. Cronos Group's return on equity of 6.46% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-73.95%	-29.85%	-3.83%
Cronos Group	38.95%	6.46%	-3.73%

Company	Overall Sentiment
Canopy Growth	Positive
Cronos Group	Neutral

Summary

Cronos Group beats Canopy Growth on 11 of the 16 factors compared between the two stocks.

How does Canopy Growth compare to Cara Operations?

Cara Operations (TSE:CARA) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Canopy Growth has a consensus price target of C$1.88, suggesting a potential upside of 73.61%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than Cara Operations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cara Operations	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

4.3% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cara Operations has a net margin of 0.00% compared to Canopy Growth's net margin of -73.95%. Cara Operations' return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cara Operations	N/A	N/A	N/A
Canopy Growth	-73.95%	-29.85%	-3.83%

In the previous week, Canopy Growth had 1 more articles in the media than Cara Operations. MarketBeat recorded 1 mentions for Canopy Growth and 0 mentions for Cara Operations. Canopy Growth's average media sentiment score of 0.71 beat Cara Operations' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
Cara Operations	Neutral
Canopy Growth	Positive

Cara Operations has higher earnings, but lower revenue than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cara Operations	N/A	N/A	N/A	N/A	N/A
Canopy Growth	C$293.63M	1.56	-C$1.05B	-C$0.67	N/A

Summary

Canopy Growth beats Cara Operations on 8 of the 11 factors compared between the two stocks.

How does Canopy Growth compare to Knight Therapeutics?

Canopy Growth (TSE:WEED) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Canopy Growth presently has a consensus target price of C$1.88, indicating a potential upside of 73.61%. Knight Therapeutics has a consensus target price of C$9.50, indicating a potential downside of 11.05%. Given Canopy Growth's higher probable upside, analysts clearly believe Canopy Growth is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

4.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 22.8% of Knight Therapeutics shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Canopy Growth has a beta of 2.406513, suggesting that its share price is 141% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.449151, suggesting that its share price is 145% less volatile than the broader market.

Knight Therapeutics has a net margin of 2.72% compared to Canopy Growth's net margin of -73.95%. Knight Therapeutics' return on equity of 1.91% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-73.95%	-29.85%	-3.83%
Knight Therapeutics	2.72%	1.91%	0.51%

In the previous week, Canopy Growth and Canopy Growth both had 1 articles in the media. Canopy Growth's average media sentiment score of 0.71 beat Knight Therapeutics' score of 0.32 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Knight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Knight Therapeutics has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$293.63M	1.56	-C$1.05B	-C$0.67	N/A
Knight Therapeutics	C$547.31M	1.92	-C$30.73M	C$0.15	71.20

Summary

Knight Therapeutics beats Canopy Growth on 11 of the 15 factors compared between the two stocks.

How does Canopy Growth compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

DRI Healthcare Trust has a beta of 0.096953, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 2.406513, suggesting that its stock price is 141% more volatile than the broader market.

DRI Healthcare Trust has higher earnings, but lower revenue than Canopy Growth. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DRI Healthcare Trust	C$172.34M	5.79	C$9.73M	-C$0.80	N/A
Canopy Growth	C$293.63M	1.56	-C$1.05B	-C$0.67	N/A

0.8% of DRI Healthcare Trust shares are held by institutional investors. Comparatively, 4.3% of Canopy Growth shares are held by institutional investors. 0.1% of DRI Healthcare Trust shares are held by company insiders. Comparatively, 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Canopy Growth had 1 more articles in the media than DRI Healthcare Trust. MarketBeat recorded 1 mentions for Canopy Growth and 0 mentions for DRI Healthcare Trust. Canopy Growth's average media sentiment score of 0.71 beat DRI Healthcare Trust's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
DRI Healthcare Trust	Neutral
Canopy Growth	Positive

DRI Healthcare Trust has a net margin of 5.02% compared to Canopy Growth's net margin of -73.95%. DRI Healthcare Trust's return on equity of 2.06% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DRI Healthcare Trust	5.02%	2.06%	4.22%
Canopy Growth	-73.95%	-29.85%	-3.83%

DRI Healthcare Trust currently has a consensus price target of C$25.60, suggesting a potential upside of 40.89%. Canopy Growth has a consensus price target of C$1.88, suggesting a potential upside of 73.61%. Given Canopy Growth's higher possible upside, analysts clearly believe Canopy Growth is more favorable than DRI Healthcare Trust.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Canopy Growth beats DRI Healthcare Trust on 9 of the 17 factors compared between the two stocks.

Get Canopy Growth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WEED vs. The Competition

Export

Metric	Canopy Growth	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$444.19M	C$12.35B	C$7.25B	C$12.64B
Dividend Yield	4.80%	2.63%	2.52%	6.34%
P/E Ratio	-1.57	807.81	275.44	37.52
Price / Sales	1.51	748.69	562.05	8.46
Price / Cash	1.63	86.65	77.16	82.29
Price / Book	0.64	9.26	10.64	4.37
Net Income	-C$1.05B	C$2.83B	C$3.49B	C$299.09M
7 Day Performance	-16.67%	-3.62%	-3.21%	-0.16%
1 Month Performance	-20.45%	-7.66%	-7.65%	-2.19%
1 Year Performance	-45.03%	-5.44%	2.92%	14.38%

Canopy Growth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
WEED Canopy Growth	2.3931 of 5 stars	C$1.05 -2.8%	C$1.88 +78.6%	-43.8%	C$444.19M	C$293.63M	N/A	1,128
MJN Cronos Group	N/A	C$12.15 -1.9%	N/A	+0.0%	C$1.73B	N/A	N/A	7,600
CRON Cronos Group	1.7158 of 5 stars	C$4.67 +0.4%	C$4.92 +5.3%	+29.0%	C$1.72B	C$179.09M	24.58	610
CARA Cara Operations	N/A	N/A	N/A	N/A	C$1.62B	N/A	N/A	80
GUD Knight Therapeutics	0.5858 of 5 stars	C$10.54 +1.7%	C$9.50 -9.9%	+85.1%	C$1.04B	C$547.31M	70.27	830

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:WEED) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Canopy Growth (WEED) Competitors

WEED vs. MJN, CRON, CARA, GUD, and DHT.UN

How does Canopy Growth compare to Cronos Group?

Summary

How does Canopy Growth compare to Cronos Group?

Summary

How does Canopy Growth compare to Cara Operations?

Summary

How does Canopy Growth compare to Knight Therapeutics?

Summary

How does Canopy Growth compare to DRI Healthcare Trust?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WEED vs. The Competition

Canopy Growth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Canopy Growth (WEED) Competitors

WEED vs. MJN, CRON, CARA, GUD, and DHT.UN

How does Canopy Growth compare to Cronos Group?

Is WEED or MJN more profitable?

Does the media favor WEED or MJN?

Do analysts prefer WEED or MJN?

Do institutionals and insiders hold more shares of WEED or MJN?

Which has preferable earnings & valuation, WEED or MJN?

Summary

How does Canopy Growth compare to Cronos Group?

Do institutionals & insiders hold more shares of WEED or CRON?

Which has better valuation and earnings, WEED or CRON?

Which has more volatility & risk, WEED or CRON?

Do analysts recommend WEED or CRON?

Is WEED or CRON more profitable?

Does the media prefer WEED or CRON?

Summary

How does Canopy Growth compare to Cara Operations?

Do analysts prefer CARA or WEED?

Do insiders & institutionals believe in CARA or WEED?

Is CARA or WEED more profitable?

Does the media favor CARA or WEED?

Which has preferable valuation and earnings, CARA or WEED?

Summary

How does Canopy Growth compare to Knight Therapeutics?

Do analysts recommend WEED or GUD?

Do insiders and institutionals believe in WEED or GUD?

Which has more volatility and risk, WEED or GUD?

Is WEED or GUD more profitable?

Does the media refer more to WEED or GUD?

Which has better earnings and valuation, WEED or GUD?

Summary

How does Canopy Growth compare to DRI Healthcare Trust?

Which has more volatility & risk, DHT.UN or WEED?

Which has stronger earnings and valuation, DHT.UN or WEED?

Do insiders & institutionals hold more shares of DHT.UN or WEED?

Does the media favor DHT.UN or WEED?

Is DHT.UN or WEED more profitable?

Do analysts prefer DHT.UN or WEED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WEED vs. The Competition

Canopy Growth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools